Stimulation of anti-melanoma immune effectors via modified tumour cells exhibiting inhibited IGF-I and low CD9.
Modified melanoma cells (B16-F0.MOD) characterized by inhibited IGF-I, CD9 low but not their wild-type counterparts (B16-F0.WT), IGF-I positive, CD9 high, were shown to be immunogenic for syngeneic hosts. C57BL/6 syngeneic recipients vaccinated with B16-F0.MOD cells developed immune effectors that were observed at the humoral as well as cellular levels. These immune effectors were shown to be capable of controlling in vitro tumour growth and in vivo tumour progression.